Text size

Federal prosecutors in Philadelphia unsealed a criminal price-fixing case Wednesday against two executives from a small maker of generic drugs. But the filing suggests that the defendants are cooperating in a much larger antitrust investigation that will reach the biggest firms in the industry, including Teva Pharmaceutical Industries (ticker: TEVA) and Mylan (MYL), which were each named Thursday in a civil antitrust case filed in Connecticut by the attorneys general of 20 states that gives greater detail on the same alleged conspiracy. Investors are valuing Teva at $37.5 billion and Mylan at $20 billion.

For a year, a number of generic companies have disclosed their receipt of government subpoenas and assured shareholders that they were cooperating with investigations of the industry, which supplies almost 90% of the nation’s prescription drugs and has about $75 billion in annual sales. The criminal antitrust case in Philadelphia presented its charges in a pleading known as an “information,” which means that prosecutors have probably secured the cooperation of Jeffrey A. Glazer and Jason T. Malek, former executives at Heritage Pharmaceuticals, a privately-held drugmaker in Eatontown, N.J.. The criminal case alleges that from 2013 to 2015 the two conspired with unnamed competitors to fix prices, rig bids and allocate customers for doxycycline, an antibiotic that doctors prescribe for severe acne. They’re also charged with fixing prices for the diabetes drug glyburide.

Heritage fired the two executives in August and sued them recently in a New Jersey federal court where the company accused them of an elaborate scheme to embezzle millions of dollars from the company, which Glazer founded in 2005 and then sold to India’s Emcure Pharmaceuticals. “We are deeply disappointed by the misconduct and are committed to ensuring it does not happen again,” Heritage said in a written statement. “We are fully cooperating with all aspects of the Department of Justice’s continuing investigation.”

Because of the continuing probe by the DOJ and Federal Bureau of investigation, the Philadelphia court filings withheld many details--even omitting the name of Glazer and Malek’s former employer Heritage. But even though the states’ civil antitrust complaint has many lines redacted, it names more names and includes among its defendants Heritage, Teva, Mylan and other generic companies like India’s Aurobindo Pharma (524804.India) and Australia’s Mayne Pharma Group (MYX.Australia).

Generic drug prices leapt by an average of nearly 450% from 2013 to 2014, notes the states’ antitrust suit. It says Connecticut started investigating the suspicious price increases in July 2014 and uncovered “evidence of a broad, well-coordinated and long running series of conspiracies to fix prices and allocate markets” for certain generic drugs. It alleges that the defendants “and other generic drug manufacturers” met at trade shows and conferences to illegally discuss upcoming bids and pricing strategies over dinner and rounds of golf. Female executives shared competitive information at gatherings dubbed “Women in the Industry” and “Girls Night Out.”

In what the states describe as merely their “initial civil action,” the complaint seeks an injunction and disgorged profits from alleged price fixing on the same two drugs cited in the federal criminal case. The complaint cites phone calls and emails between Heritage’s ex-president Malek and unnamed executives at Mylan, in which they allegedly allocated market share for the antibiotic doxycycline and agreed to “walk away” from each other’s pharmacy and wholesaler customers. Malek also allegedly talked directly with a Teva executive in a scheme to raise the price of the diabetes drug glyburide by 200%.

Mylan is already suffering from the political uproar over its price hikes for EpiPen, the auto-injector for severe allergic reactions. In the last year and a half, its shares have been cut in half to a recent $38. Responding to our questions about the antitrust charges, Mylan spokesperson Nina Devlin said: “To date, we know of no evidence that Mylan participated in price fixing.”

As drug prices came under fire, Teva share price suffered a similar drop, to $37. Mylan traded at $38 recently. “To date, we have not found any evidence of price fixing within Teva,” said spokesperson Denise Bradley, “and so on the facts we vigorously deny any allegations of wrongdoing.”

This week’s legal developments had little impact on the companies’ share prices. In a Wednesday comment, Leerink Partners analysts Jason Gerberry and Etzer Darout struck a hopeful tone in noting that the two drugs mentioned in the antitrust cases were relatively small sellers, so a judgment for disgorged profits wouldn’t hurt their generic makers.

But the government officials announcing each of the cases took pains to point out that their investigations continue, pursuing other drugs and other generic firms.

Email: editors@barrons.com

Follow @blalpert

Follow Barron’s on Twitter

Like Barron’s on Facebook